In sum, these data suggest that, in individuals with obesity and insulin resistance, GLP-1, GIP and glucagon are likely to increase AT’s metabolic efficiency despite this effect being attained via different mechanisms and potentially acting in synergy. The gene discussed is GLP1R; the disease is Insulin resistance.